Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00438217

Acronym

CPP-EDG 01

Enrollment

100

Registered

2007-02-22

Start date

Unknown

Completion date

Unknown

Last updated

2007-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Precocious Puberty

Keywords

precocious puberty, genetics, environmental factors

Brief summary

The goal of CPP-EDG 01 study is to assess possible genetic and/or environmental parameters which may influence the growth rate of children affected by precocious puberty. In this view, we are collecting clinical data and biological samples of children attended as outpatients at the Pediatric Endocrine Center of Pisa from 1998 to present (the study is still open). From biological (blood) samples, gene polymorphisms such as endocrine disruptor levels are determined and compared to different growth pattern of pediatric patients treated with different GnRH agonists.

Interventions

DRUGTriptorelin (GnRH agonists)

DRUGLeuprolide (GnRH agonists)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinica diagnosis of central precocious puberty * Diagnosis is based on growth spurt, bone age advancement, positive GnRH agonist stimulating test, pubertal sex steroid levels before 8 years of age for female and 9 years for male, respectively

Exclusion criteria

* Thyroid disorders * Peripheric diagnosis of precocious puberty * Genetic disorders

Countries

Italy

Contacts

Primary ContactFrancesco Massart, MD, PhD

massart@med.unipi.it0039 050 99 3600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026